Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes

References

• NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtWPreserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitusJ Clin Invest1993913013078423228
   PubMed Web of Science ®Google Scholar
• VisbollTKrarupTDeaconCFMadsbadSHolstJJReduced postprandial concentrations of intact biologically active glucagon-like peptide in patients with type 2 diabetic patientsDiabetes20015060961311246881
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBMadsbadSHolstJJDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab2001863717372311502801
   PubMed Web of Science ®Google Scholar
• MuscelliEMariACasolaroASeparate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic subjectsDiabetes2008571340134818162504
   PubMed Web of Science ®Google Scholar
• MeierJJGallwitzBAskenasMSecretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetesDiabetologia2005481872188116010522
   PubMed Web of Science ®Google Scholar
• VilsbøllTKrarupTSonneJIncretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitusJ Clin Endocrinol Metab2003882706271312788877
   PubMed Web of Science ®Google Scholar
• VollmerKHolstJJBallerBPredictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose toleranceDiabetes20085767868718057091
   PubMed Web of Science ®Google Scholar
• LaaksoMZilinskaiteJHansenTInsulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 studyDiabetologia20085150251118080106
   PubMed Web of Science ®Google Scholar
• KjemsLLHolstJJVolundAMadsbadSThe influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjectsDiabetes20035238038612540611
   PubMed Web of Science ®Google Scholar
• HolstJJToft-NielsenMBOrskovCNauckMWillmsBOn the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjectsAnn N Y Acd Sci1996805729736
   Web of Science ®Google Scholar
• SchirraJWankUArnoldRGokeBKatschinskiMEffects of glucagon-like peptide-1 (7–36) amide on motility and sensation of the proximal stomach in humansGut20025034134811839712
   PubMed Web of Science ®Google Scholar
• ElahiDMcAloon-DykeMFukagawaNKThe insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjectsRegul Pept19945163748036284
   PubMed Web of Science ®Google Scholar
• KiefferTJMcIntoshCHPedersonRADegradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology1995136358535967628397
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAMeierJHuckingKHolstJJDegradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptideJ Clin Endocrinol Metab2000853575358111061504
   PubMed Web of Science ®Google Scholar
• DeaconCFNauckMAToft-NielsenMBPridalLWillmsBHolstJJBoth subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjectsDiabetes199544112611317657039
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDThe effect of dipeptidyl peptidase 4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double blind, placebo-controlled crossover studyClin Endocrinol (Oxf)200869573774418331607
   PubMed Web of Science ®Google Scholar
• ConarelloSLLiZRonanJRoyRSMice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistancePNAS20031006825683012748388
   PubMed Web of Science ®Google Scholar
• PedersnRAWhiteHASchlenzigDPaulyRPMcIntoshCHDemuthHUImproved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor Ile-thiazolidedeMetabolism199848385389
   Web of Science ®Google Scholar
• PospisilikJAStaffordSGDemuthHULong-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker ratsDiabetes20025194395011916911
   PubMed Web of Science ®Google Scholar
• PospisilikJAStaffordSGDemuthHUMcIntoshCHPedersonRALong-term treatment with the dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zuker rat: a euglycemic-hyperinsulinemic clamp studyDiabetes2002512677268312196458
   PubMed Web of Science ®Google Scholar
• SudreBBroquaPWhiteRBChronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty ratsDiabetes2002511461146911978643
   PubMed Web of Science ®Google Scholar
• PospisilikJAMartinJDotyTDipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin- induced diabetic ratsDiabetes20035274175012606516
   PubMed Web of Science ®Google Scholar
• MuJWoodsJZhouYPChronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of Type 2 diabetesDiabetes2006551695170416731832
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetesDiabetes2007561475148017303799
   PubMed Web of Science ®Google Scholar
• AhrenBLandin-OlssonMJanssonPASvenssonMHolmesDSchweizerAInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab2004892078208415126524
   PubMed Web of Science ®Google Scholar
• AzumaKRadikovaZMancinoJMeasurement of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab20089345946418042650
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab2007921249125517244786
   PubMed Web of Science ®Google Scholar
• Dalla ManCBockGieslerPDDipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetesDiabetes Care2009321141818931099
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJRendellMEffects of the dipeptidyl peptidase IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care200831303517947341
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejaherSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrin Metab200994412361243
   PubMed Web of Science ®Google Scholar
• PrigeonRLQuddusiSPatyBD’AlessioDASuppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effectAm J Physiol Endocrinol Metab20032854E70170712773303
   PubMed Web of Science ®Google Scholar
• D’AlessioDAPrigeonRLEnsinckJWEnteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide IDiabetes19954412143314377589851
   PubMed Web of Science ®Google Scholar
• VellaAShahPBasuRBasuAHolstJJRizzaRAEffect of glucagon-like peptide 1(7–36) amide on glucose effectiveness and insulin action in people with type 2 diabetesDiabetes200049461161710871199
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPThe effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover studyClin Endocrinol200869737744
   PubMed Web of Science ®Google Scholar
• NauckMAEl-OuaghlidiAThe therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide 1Diabetologia20064860861115761719
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsDiabetologia20054861261515759106
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtWPreserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusJ Clin Invest1993913013078423228
   PubMed Web of Science ®Google Scholar
• NakagawaASatakeHNakabayashiHReceptor gene expression of glucagon-like peptide-1, but not glucose dependent insulinotropic polypeptide, in rat nodose ganglion cellsAuton Neurosci2004110364314766323
   PubMed Web of Science ®Google Scholar
• NishizawaMNakabyashiHUchidaKNakagawaANiijimaAThe hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose dependent peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal veinJ Auton Nerv Syst1996611491548946334
   PubMedGoogle Scholar
• MeierJJGallwitzBSalmenSNormalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetesJ Clin Endocrinol Metab2003882719272512788879
   PubMed Web of Science ®Google Scholar
• MentleinRDipeptidyl-peptidaseIV(CD26) – role in the inactivation of regulatory peptidesRegul Pept19998592410588446
   PubMed Web of Science ®Google Scholar
• FlockGZhnagGLDuttaroyADruckerDJThe classic incretin receptors for GLP-1 and GIP are essential for the sustained glucoregulatory actions of vildagliptin in miceDiabetologia200649107
   Web of Science ®Google Scholar
• HansotiaTBaggioLLDelmeireDDouble incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitorsDiabetes2004531326133515111503
   PubMed Web of Science ®Google Scholar
• HeHTranPSmithHAbsorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humansDrug Metab Dispos200937353654419074975
   PubMed Web of Science ®Google Scholar
• HeYLSerraDWangYPharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusClin Pharmakinet2007467577588
   Google Scholar
• SunkaraGSaboRWangYDose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteersJ Clin Pharmacol2007471152115817656620
   PubMed Web of Science ®Google Scholar
• HeYLSaboRBalexSAbsolute bioavailability of vildagliptin in healthy subjectsClin Pharmacol Ther200679P38
   Web of Science ®Google Scholar
• HeYLLigueros-SaylanMSunkaraGVildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjectsJ Clin Pharmacol200848859517986525
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEfficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycæmiaDiabetes Obes Metab20081067568218248490
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEvidence that vildagliptin attenuates deterioration of glycæmic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycæmiaDiabetes Obes Metab2008101114112418355325
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple dose studyHorm Metab Res20073921822317373638
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierJFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA1C over 1 year in drug-naïve patients with type 2 diabetesDiabet Med20072495596117509069
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care20073021722317259484
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRPCressierFCouturierADejagerSEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab20073017518517300593
   PubMed Web of Science ®Google Scholar
• PanCYangWBaronJPComparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabet Med20082543544118341596
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab20091115716619125777
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab2008101047105618284434
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronMARochotteMADejagerSVildagliptin in combination with pioglitazone improves glycæmic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab2007916617417300592
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycæmic control in type 2 diabetesDiabetologia2007501148115317387446
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naïve elderly patientsDiabetes Care2007393017302217878242
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetesJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• YanSMarguetDDobersJReutterWFanHDeficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogenEur J Immunol2003331519152712778469
   PubMed Web of Science ®Google Scholar
• VanhoofGGoossensFDe MeesterIHendricksDScharpeSProline motifs in peptides and their biological processingFASEB J199597367447601338
   PubMed Web of Science ®Google Scholar